Evidence map›Paper›PMID 38663887›Full record

ArticleBMJ open respiratory research2024

Long COVID exhibits clinically distinct phenotypes at 3-6 months post-SARS-CoV-2 infection: results from the P4O2 consortium.

Jelle M Blankestijn, Mahmoud I Abdel-Aziz, Nadia Baalbaki, Somayeh Bazdar, Inés Beekers, Rosanne J H C G Beijers, Lizan D Bloemsma, Merel E B Cornelissen, Debbie Gach, Laura Houweling and 19 more

Abstract read
In one paragraph

Article in BMJ open respiratory research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Jelle M BlankestijnDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands j.m.blankestijn@amsterdamumc.nl.ORCID http://orcid.org/0009-0006-2047-0888
Mahmoud I Abdel-AzizDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Nadia BaalbakiDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Somayeh BazdarDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Inés BeekersORTEC, Zoetermeer, Zuid-Holland, The Netherlands.
Rosanne J H C G BeijersDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Lizan D BloemsmaDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Merel E B CornelissenDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Debbie GachDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Laura HouwelingDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Sebastiaan HolverdaLongfonds, Amersfoort, Utrecht, The Netherlands.
John J L JacobsORTEC, Zoetermeer, Zuid-Holland, The Netherlands.
Reneé JonkerDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Ivo van der LeeDepartment of Pulmonology, Spaarne Gasthuis, Haarlem, The Netherlands.
Paulien M A LindersDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Firdaus A A Mohamed HoeseinDepartment of Radiology, University Medical Center Utrecht and Utrecht University, Utrecht, The Netherlands.
Lieke C E NoijDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Esther J NossentDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Marianne A van de PolDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Daphne W SchamineeDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Annemie M W J ScholsUniversiteit Maastricht School of Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands.
Lisanne T SchuurmanDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Brigitte SondermeijerDepartment of Pulmonology, Spaarne Gasthuis, Haarlem, The Netherlands.
J J Miranda GeelhoedDepartment of Respiratory Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Joop P van den BerghDepartment of Respiratory Medicine, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands.
Els J M WeersinkDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Yolanda de Wit-van WijckDepartment of Pulmonary Medicine, Amsterdam UMC Locatie AMC, Amsterdam, The Netherlands.
Anke H Maitland-van der ZeeDepartment of Respiratory Medicine, Amsterdam UMC, Amsterdam, The Netherlands.
P4O2 consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFour months after SARS-CoV-2 infection, 22%-50% of COVID-19 patients still experience complaints. Long COVID is a heterogeneous disease and finding subtypes could aid in optimising and developing treatment for the individual patient.

methodsData were collected from 95 patients in the P4O2 COVID-19 cohort at 3-6 months after infection. Unsupervised hierarchical clustering was performed on patient characteristics, characteristics from acute SARS-CoV-2 infection, long COVID symptom data, lung function and questionnaires describing the impact and severity of long COVID. To assess robustness, partitioning around medoids was used as alternative clustering.

resultsThree distinct clusters of patients with long COVID were revealed. Cluster 1 (44%) represented predominantly female patients (93%) with pre-existing asthma and suffered from a median of four symptom categories, including fatigue and respiratory and neurological symptoms. They showed a milder SARS-CoV-2 infection. Cluster 2 (38%) consisted of predominantly male patients (83%) with cardiovascular disease (CVD) and suffered from a median of three symptom categories, most commonly respiratory and neurological symptoms. This cluster also showed a significantly lower forced expiratory volume within 1 s and diffusion capacity of the lung for carbon monoxide. Cluster 3 (18%) was predominantly male (88%) with pre-existing CVD and diabetes. This cluster showed the mildest long COVID, and suffered from symptoms in a median of one symptom category.

conclusionsLong COVID patients can be clustered into three distinct phenotypes based on their clinical presentation and easily obtainable information. These clusters show distinction in patient characteristics, lung function, long COVID severity and acute SARS-CoV-2 infection severity. This clustering can help in selecting the most beneficial monitoring and/or treatment strategies for patients suffering from long COVID. Follow-up research is needed to reveal the underlying molecular mechanisms implicated in the different phenotypes and determine the efficacy of treatment.

Indexed as

COVID-19PhenotypePost-Acute COVID-19 SyndromeSARS-CoV-2AdultAgedCluster AnalysisCohort StudiesFemaleForced Expiratory VolumeHumansMaleMiddle AgedRespiratory Function TestsSeverity of Illness IndexTime FactorsCOVID-19

Identifiers

PMID38663887
PMCPMC11043734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.